BP
Bharat Parenterals Ltd (BPLPHARMA)
₹2,314.00
Mkt cap
₹1,655 Cr
P/E ratio
1,334.00
P/B
4.80
Div yield
0.04%
ROE
−2.54%
ROCE
−1.87%
EPS (TTM)
₹1.73
Book value
₹482
52W range
46–2,493
Sector
Healthcare
Price history
Previous close
Incorporated in 1992, Bharat Parenterals Ltd is in the business of manufacturing and marketing of formulations [1]
NSE BPLPHARMABSE 541096
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthModerate
TechnicalsNeutral
52-week range
−7.17% from high₹2,314
₹46+4,919.52% from low₹2,493
Current
₹2,314.00
Prev close
₹2,385.00
Day
−2.98%
Price performance
1D
−2.98%
1W
+9.11%
1M
+30.29%
3M
+78.73%
6M
—
1Y
—
YTD
+77.05%
Financials
Revenue, profit & margin
P/E ratio
1,334.0×
BPLPHARMA is 3,962% above the sector median of 32.8×
BPLPHARMA1,334.0×
Sector median32.8×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 | 60 | 68 | 93 | 72 | 72 | 104 | 116 | 65 | 65 | 100 | 94 | 136 | |
| YoY Sales growth | -27% | +1% | +33% | +32% | +20% | +21% | +53% | +25% | -10% | -10% | -4% | -19% | +111% | |
| Expenses | 55 | 53 | 67 | 88 | 79 | 69 | 102 | 102 | 64 | 63 | 100 | 85 | 113 | |
| Operating Profit | 4 | 7 | 1 | 4 | -8 | 4 | 2 | 14 | 1 | 2 | -1 | 9 | 24 | |
| OPM % | 7% | 11% | 1.5% | 4.8% | -11% | 5% | 2.1% | 12% | 1.3% | 2.7% | -0.5% | 9% | 17% | |
| Other Income | 3 | 1 | 3 | 3 | 4 | 3 | 2 | 1 | 4 | 1 | 4 | 1 | 3 | |
| Interest | 1 | 1 | 1 | 3 | 3 | 3 | 4 | 4 | 3 | 3 | 3 | 2 | 3 | |
| Depreciation | 2 | 2 | 4 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 9 | 9 | 9 | |
| Profit before tax | 5 | 5 | -1 | -5 | -15 | -6 | -8 | 3 | -7 | -8 | -8 | -2 | 14 | |
| Tax % | 46% | 33% | 88% | 85% | 14% | 43% | 14% | 134% | 18% | 17% | -3% | 138% | 16% | |
| Net Profit | 2 | 4 | -3 | -9 | -18 | -8 | -9 | -1 | -9 | -10 | -8 | -4 | 12 | |
| EPS in Rs | 6.05 | 6.50 | -0.52 | 1.96 | -11.50 | -2.42 | -6.86 | 11.94 | -10.50 | -6.37 | -6.96 | 1.47 | 13.67 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202667.20%Promoter
Promoters67.20%
FIIs0.11%
DIIs1.29%0.09
Public31.40%0.09
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,900.00 | 37.05 | 4,55,874 | 0.84% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,178.00 | 86.84 | 2,96,741 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,611.00 | 80.79 | 1,75,388 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,306.00 | 92.99 | 1,24,596 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,202.90 | 26.48 | 1,19,990 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,400.90 | 41.79 | 1,17,013 | 0.57% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,418.50 | 36.90 | 1,14,599 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Bharat Parenter. | ₹2,401.00 | 1,334.48 | 1,655 | 0.04% | 12 | +230.11% | 136 | +110.89% | −1.87% |
| Median: 160 Co. | ₹445.67 | 32.84 | 2,004 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Concall transcripts14
Announcements5
Clarification sought from Bharat Parenterals Ltd 19 Nov - Exchange has sought clarification from Bharat Parenterals Ltd on November 19, 2026 with reference to significant movement in price, in order to ensure that investors …Announcement under Regulation 30 (LODR)-Press Release / Media Release 5 Nov - Innoxel received USFDA EIR on Nov 4, 2026; Vadodara facility cleared for commercial injectable operations.Announcement under Regulation 30 (LODR)-Earnings Call Transcript 2 NovAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 30 Oct - Q2FY27 earnings conference call audio recording hosted on company website on October 30, 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Oct - Please find the enclosed copies of the newspaper publication regarding unaudited standalone and Consolidate Financial result for the quarter and half-year ended on September 30, …






